gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

Many tumor-associated antigens are nonmutated, poorly immunogenic tissue differentiation antigens. Their weak immunogenicity may be due to “self”-tolerance. To induce autoreactive T cells, we studied immune responses to gp100/pmel 17, an antigen naturally expressed by both normal melanocytes and melanoma cells. Although a recombinant vaccinia virus (rVV) encoding the mouse homologue of gp100 was nonimmunogenic, immunization of normal C57BL/6 mice with the rVV encoding the human gp100 elicited a specific CD8+ T cell response. These lymphocytes were cross-reactive with mgp100 in vitro and treated established B16 melanoma upon adoptive transfer. To understand the mechanism of the greater immunogenicity of the human version of gp100, we characterized a 9-amino acid (AA) epitope, restricted by H-2Db, that was recognized by the T cells. The ability to induce specific T cells with human but not mouse gp100 resulted from differences within the major histocompatibility complex (MHC) class I–restricted epitope and not from differences elsewhere in the molecule, as was evidenced by experiments in which mice were immunized with rVV containing minigenes encoding these epitopes. Although the human (hgp10025–33) and mouse (mgp10025–33) epitopes were homologous, differences in the three NH2-terminal AAs resulted in a 2-log increase in the ability of the human peptide to stabilize “empty” Db on RMA-S cells and a 3-log increase in its ability to trigger interferon γ release by T cells. Thus, the fortuitous existence of a peptide homologue with significantly greater avidity for MHC class I resulted in the generation of self-reactive T cells. High-affinity, altered peptide ligands might be useful in the rational design of recombinant and synthetic vaccines that target tissue differentiation antigens expressed by tumors.

[1]  S. Rosenberg,et al.  Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. , 1998, Journal of immunological methods.

[2]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[3]  B. Moss,et al.  Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.

[4]  C. Janeway,et al.  The imprint of intrathymic self-peptides on the mature T cell receptor repertoire. , 1997, Immunity.

[5]  E. Engleman,et al.  Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. , 1997, Journal of immunology.

[6]  J. Shabanowitz,et al.  Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. , 1997, Immunity.

[7]  N. Restifo,et al.  Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. , 1997, Methods.

[8]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[9]  J. Berzofsky,et al.  Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. , 1997, Journal of immunology.

[10]  E. Sercarz,et al.  Diversification of  T Cell Responses to Carboxy-terminal Determinants within the 65-kD Heat-shock Protein Is Involved in Regulation of Autoimmune Arthritis , 1997, The Journal of experimental medicine.

[11]  S. Rosenberg Cancer vaccines based on the identification of genes encoding cancer regression antigens. , 1997, Immunology today.

[12]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Yewdell,et al.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. , 1997, Journal of immunology.

[14]  S. Rosenberg,et al.  Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. , 1997, Journal of immunotherapy.

[15]  B. Moss Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  N. Restifo The new vaccines: building viruses that elicit antitumor immunity. , 1996, Current opinion in immunology.

[17]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[18]  J. Kapp,et al.  Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake , 1996, The Journal of experimental medicine.

[19]  S. Rosenberg,et al.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. , 1996, Journal of immunology.

[20]  Epitope spreading. , 1996, Current opinion in immunology.

[21]  D. Kioussis,et al.  Low avidity recognition of self-antigen by T cells permits escape from central tolerance. , 1995, Immunity.

[22]  J. Frelinger,et al.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Linsley,et al.  Induction and reversal of long-lived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. , 1995, Journal of immunology.

[24]  A. Lanzavecchia,et al.  Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants , 1995, The Journal of experimental medicine.

[25]  R. Anderson,et al.  Antigen processing in vivo and the elicitation of primary CTL responses. , 1995, Journal of immunology.

[26]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[27]  M. Mamula Lupus Autoimmunity; From Peptides to Particles , 1995, Immunological reviews.

[28]  Dorothy Bennett,et al.  Mouse silver mutation is caused by a single base insertion in the putative cytoplasmic domain of Pmel 17 , 1995, Nucleic Acids Res..

[29]  K. Heeg,et al.  In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. , 1995, Vaccine.

[30]  B. Kwon,et al.  The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function. , 1994, The Journal of biological chemistry.

[31]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Mamula,et al.  B cells process and present lupus autoantigens that initiate autoimmune T cell responses. , 1994, Journal of immunology.

[33]  K. Gilbert,et al.  T cell clonal anergy. , 1994, Chemical immunology.

[34]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[35]  K. Urabe,et al.  The tyrosinase gene family--interactions of melanogenic proteins to regulate melanogenesis. , 1994, Cellular & molecular biology research.

[36]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[37]  M. Mamula The inability to process a self-peptide allows autoreactive T cells to escape tolerance , 1993, The Journal of experimental medicine.

[38]  J. Yewdell,et al.  Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes , 1992, Cell.

[39]  P. Matzinger,et al.  B cells turn off virgin but not memory T cells. , 1992, Science.

[40]  C. Janeway,et al.  Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. , 1992, Journal of immunology.

[41]  N. Copeland,et al.  A second tyrosinase‐related protein, TRP‐2, maps to and is mutated at the mouse slaty locus. , 1992, The EMBO journal.

[42]  Hidde L. Ploegh,et al.  Empty MHC class I molecules come out in the cold , 1990, Nature.

[43]  P. Marrack,et al.  T cell tolerance by clonal elimination in the thymus , 1987, Cell.

[44]  K. Makino,et al.  Cloning and sequencing of mouse tyrosinase cDNA. , 1987 .

[45]  S. Shibahara,et al.  Cloning and expression of cDNA encoding mouse tyrosinase. , 1986, Nucleic acids research.

[46]  K. Rock,et al.  Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. , 1985, Journal of immunology.